Navigation Links
NORD and DIA to Host Conference on Rare Diseases and Orphan Products
Date:9/14/2011

WASHINGTON, Sept. 14, 2011 /PRNewswire-USNewswire/ -- The National Organization for Rare Disorders (NORD) and the Drug Information Association (DIA) will host the U.S. Conference on Rare Diseases and Orphan Products in Washington, D.C. October 11-13.  Everyone with an interest in rare diseases or orphan products is invited.

(Logo: http://photos.prnewswire.com/prnh/20110719/DC37656LOGO-b)

"This conference will be truly unique in that it will draw together all the stakeholders from government, industry, academia and patient organizations," said Peter L. Saltonstall, president and CEO of NORD.  "Most of the nearly 7,000 rare diseases don't have FDA-approved treatments.  The purpose of this conference is to bring everyone together—government, industry, medical researchers, investors and patients—to examine the challenges and opportunities."

NORD is a nonprofit organization representing all Americans affected by rare diseases.  DIA is a nonprofit, global professional association of members involved in pharmaceutical and medical device discovery, development, and management.

Senior staff from the National Institutes of Health (NIH) and Food and Drug Administration (FDA) will speak at the conference, along with thought leaders from the pharmaceutical industry, medical researchers, and the investment community.  Speakers will include:

  • NIH Director Francis Collins, MD, PhD
  • Social Security Commissioner Michael Astrue
  • Christopher P. Austin, MD, PhD, Scientific Director, NIH Center for Translational Therapeutics
  • Janet Woodcock, MD, Director of FDA's Center for Drug Evaluation and Research
  • John K. Jenkins, MD, Director, Office of New Drugs, FDA Center for Drug Evaluation and Research
  • Suzanne L. Bruhn, PhD, Senior VP, Shire Human Genetic Therapies
  • Marc Dunoyer, Global Head, Rare Diseases, GlaxoSmithKline
  • Lynne Fahey McGrath, MPH, PhD, Vice President, North American Head Drug Regulatory Affairs, Novartis Oncology Corporation
  • Dennis Jackman, Senior VP, Public Affairs, CSL Behring
  • Margaret Anderson, Executive Director, FasterCures
  • Jonathan S. Leff, AB, MBA, Managing Director, Warburg Pincus
  • Jeff Allen, PhD, Executive Director, Friends of Cancer Research

While the conference is co-hosted by NORD and DIA, collaborators also include Duke University School of Medicine, the European Rare Diseases Organization (EURORDIS), FDA and NIH.  Topics will include:

  • How federal policies affect patients with rare diseases
  • NIH grant and FDA approval requirements
  • How health care reform will impact rare disease patients
  • Venture philanthropy
  • Clinical trial designs and case examples
  • The economics of investing in orphan products

Information about the conference is available on the NORD website (www.rarediseases.org) and on a special site for online registration hosted by DIA: (http://www.diahome.org/DIAHOME/FlagshipMeetings/Home.aspx?meetingid=26189.

The conference will take place at the Omni Shoreham Hotel in Washington, D.C.   For additional information, contact NORD or DIA.


'/>"/>
SOURCE National Organization for Rare Disorder (NORD)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. ViroPharma to Present at Three Upcoming Healthcare Conferences
6. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):